Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

Gynecologic Oncology

Volumn 140, Issue 2, 2016, Pages 210-214

  Kim, Kenneth H ^a   Jelovac, Danijela ^b   Armstrong, Deborah K ^b   Schwartz, Benjamin ^c   Weil, Susan C ^d   Schweizer, Charles ^d   Alvarez, Ronald D ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PLLC   (United States)

^d Morphotek Inc   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Farletuzumab; Monoclonal antibody therapy; Ovarian cancer; Pegylated liposomal doxorubicin; Platinum sensitive relapse

Indexed keywords

CARBOPLATIN; DOXORUBICIN; FARLETUZUMAB; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERHIDROSIS; HYPERSENSITIVITY; HYPESTHESIA; LIMB PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVARY CARCINOMA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 84950298371     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.11.031     Document Type: Article

References (22)

1. L.A. Dainty, J.I. Risinger, C. Morrison, and et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma Gynecol. Oncol. 105 2007 563 570 10.1016/j.ygyno.2006.10.063
2. S.D. Weitman, R.H. Lark, L.R. Coney, and et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues Cancer Res. 52 1992 3396 3401
3. G. Toffoli, C. Cenigoi, A. Russo, and et al. Overexpression of folate binding protein in ovarian cancers Int. J. Cancer 74 1997 193 198
4. Y.-L. Chen, M.-C. Chang, C.-Y. Huang, and et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response Mol. Oncol. 6 2012 360 369 10.1016/j.molonc.2011.11.010
5. W. Ebel, E.L. Routhier, B. Foley, and et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha Cancer Immun. 7 2007 6 13
6. J. Lin, J.L. Spidel, C.J. Maddage, and et al. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity Cancer Biol. Ther. 14 2013 1032 1038 10.4161/cbt.26106
7. D.K. Armstrong, A.J. White, S.C. Weil, and et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer Gynecol. Oncol. 129 2013 452 458 10.1016/j.ygyno.2013.03.002
8. Y. Wen, W.S. Graybill, R.A. Previs, and et al. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer Clin. Cancer Res. 21 2015 448 459 10.1158/1078-0432.CCR-14-1578
9. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, and et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J. Clin. Oncol. 28 2010 3323 3329 10.1200/JCO.2009.25.7519
10. P. Power, G. Stuart, A. Oza, and et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study Gynecol. Oncol. 114 2009 410 414 10.1016/j.ygyno.2009.04.037
11. L. Gladieff, A. Ferraro, G. De Rauglaudre, and et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial Ann. Oncol. 23 2012 1185 1189 10.1093/annonc/mdr441
12. M. Markman, J. Moon, S. Wilczynski, and et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 Gynecol. Oncol. 116 2010 323 325 10.1016/j.ygyno.2009.11.026
13. Human and Murine ADA Isotyping Multiplexes for Immunogenicity Testing of Protein Therapeutics Using the MT-ADA™ Assay 2013 Genalyte, Inc. San Diego, CA
14. C.J. Clopper, and E.S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
15. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J. Am. Stat. Assoc. 53 1958 457 481
16. R. Brookmeyer, and J. Crowley A confidence interval for the median survival time Biometrics 38 1982 29 41
17. J.D. Kalbfleisch, and R.L. Prentice The Statistical Analysis of Failure Time Data 1980 John Wiley & Sons, Inc.
18. M.A. Bookman, M.F. Brady, W.P. Maguire, and et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer InterGroup J. Clin. Oncol. 27 2009 1419 1425 10.1200/JCO.2008.19.1684
19. I. Vergote, D. Armstrong, G. Scambia, and et al. Phase 3 double-blind, placebo controlled study of weekly farletuzumab with carboplatin/taxane in subjects with platinum-sensitive ovarian cancer in first relapse Oral Presentation at the 18th International Meeting of the European Society of Gynaecological Oncology, October 19-22 2013 (Liverpool, UK)
20. J. Pfisterer, M. Plante, I. Vergote, and et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J. Clin. Oncol. 24 2006 4699 4707 10.1200/JCO.2006.06.0913
21. J.A. Konner, K.M. Bell-McGuinn, P. Sabbatini, and et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study Clin. Cancer Res. 16 2010 5288 5295 10.1158/1078-0432.CCR-10-0700
22. A. Javeed, M. Ashraf, A. Riaz, and et al. Paclitaxel and immune system Eur. J. Pharm. Sci. 38 2009 283 290 10.1016/j.ejps.2009.08.009